Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.40 |
| ▸ | PREP | P48147 | 1/20 | 0.40 |
| ▸ | SETD7 | Q8WTS6 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL489126 | 1.00 | CHRM2 (0.44) | CHRM2CHRM1CHRM3HSD17B10HPGD | |
| SCHEMBL489128 | 1.00 | CHRM2 (0.44) | CHRM2CHRM1CHRM3HSD17B10HPGD | |
| SCHEMBL178721 | 0.89 | HSD17B10 (0.52) | CHRM2CHRM1CHRM3HSD17B10HPGD | |
| SCHEMBL357042 | 0.89 | HSD17B10 (0.52) | CHRM2CHRM1CHRM3HSD17B10HPGD | |
| SCHEMBL357043 | 0.89 | HSD17B10 (0.52) | CHRM2CHRM1CHRM3HSD17B10HPGD | |
| Hydrochloric Acid SCHEMBL5783201 | 0.88 | HSD17B10 (0.38) | CHRM2CHRM1CHRM3HSD17B10HPGD | |
| Hydrochloric Acid SCHEMBL5783202 | 0.88 | HSD17B10 (0.38) | CHRM2CHRM1CHRM3HSD17B10HPGD | |
| SCHEMBL1202111 | 0.87 | HPGD (0.49) | HSD17B10HPGDSMN1; SMN2EPHX1PREP | |
| SCHEMBL7005690 | 0.87 | HPGD (0.49) | HSD17B10HPGDSMN1; SMN2EPHX1PREP | |
| SCHEMBL7002987 | 0.87 | HPGD (0.49) | HSD17B10HPGDSMN1; SMN2EPHX1PREP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230364070-A1 | PYRROLO[3,2-C]PYRIDIN-4-ONE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | ANTARES THERAPEUTICS, INC. | 2023-11-16 | — | — | US | disclosed |
| WO-2021252307-A1 | RIPK1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME CORP. (US) | 2021-12-16 | — | — | WO | disclosed |
| US-11149035-B2 | Chemical compounds as H—PGDS inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DFVELOPMENT LIMITED (GB) | 2021-10-19 | — | — | US | disclosed |
| US-11149035-B2 | Chemical compounds as H—PGDS inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DFVELOPMENT LIMITED (GB) | 2021-10-19 | — | — | US | disclosed |
| EP-3390384-B1 | QUINOLINE-3-CARBOXAMIDES AS H-PGDS INHIBITORS | ASTEX THERAPEUTICS LTD (GB) | 2021-09-15 | — | — | EP | disclosed |
| US-20210238162-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-08-05 | — | — | US | disclosed |
| US-20210238162-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-08-05 | — | — | US | disclosed |
| US-11053215-B2 | Heterocyclic compounds useful as Pim kinase inhibitors | INCYTE CORPORATION (US) | 2021-07-06 | — | — | US | disclosed |
| US-20200123152-A1 | Chemical Compounds as H-PGDS Inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-04-23 | — | — | US | disclosed |
| US-20200123152-A1 | Chemical Compounds as H-PGDS Inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-04-23 | — | — | US | disclosed |
| EP-3390384-A1 | QUINOLINE-3-CARBOXAMIDES AS H-PGDS INHIBITORS | Astex Therapeutics Limited (GB) | 2018-10-24 | — | — | EP | disclosed |
| US-9920032-B2 | Heterocyclic compounds useful as pim kinase inhibitors | INCYTE CORPORATION (US) | 2018-03-20 | — | — | US | disclosed |
| US-9920032-B2 | Heterocyclic compounds useful as pim kinase inhibitors | INCYTE CORPORATION (US) | 2018-03-20 | — | — | US | disclosed |
| WO-2017103851-A1 | QUINOLINE-3-CARBOXAMIDES AS H-PGDS INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2017-06-22 | — | — | WO | disclosed |
| US-20170096411-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS PIM KINASE INHIBITORS | INCYTE CORPORATION | 2017-04-06 | — | — | US | disclosed |
| US-20170096411-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS PIM KINASE INHIBITORS | INCYTE CORPORATION | 2017-04-06 | — | — | US | disclosed |
| US-20090186868-A1 | Taxane Compound Having Azetidine Ring Structure | DAIICHI SANKYO COMPANY LIMITED (JP) | 2009-07-23 | — | — | US | disclosed |
| US-20090186868-A1 | Taxane Compound Having Azetidine Ring Structure | DAIICHI SANKYO COMPANY LIMITED (JP) | 2009-07-23 | — | — | US | disclosed |
| US-20090186868-A1 | Taxane Compound Having Azetidine Ring Structure | DAIICHI SANKYO COMPANY LIMITED (JP) | 2009-07-23 | — | — | US | disclosed |
| EP-1942109-A1 | TAXANE COMPOUND WITH AZETIDINE RING STRUCTURE | Daiichi Sankyo Company, Limited (JP) | 2008-07-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11149035-B2 | Chemical compounds as H—PGDS inhibitors | HPGDS, PTGS1, PTGIS | CHRM2 2023/4885CHRM1 1441/4885CHRM3 2244/4885 |
| US-20200123152-A1 | Chemical Compounds as H-PGDS Inhibitors | HPGDS, PTGS1, PTGIS | CHRM2 2052/4885CHRM1 1476/4885CHRM3 2268/4885 |
| US-20090186868-A1 | Taxane Compound Having Azetidine Ring Structure | ABCC1, AZI2, TPD52L2 | CHRM2 2139/4885CHRM1 750/4885CHRM3 3337/4885 |
| US-11053215-B2 | Heterocyclic compounds useful as Pim kinase inhibitors | PIM1, PIM2, PIM3 | CHRM2 4853/4885CHRM1 4773/4885CHRM3 4768/4885 |
| US-20230364070-A1 | PYRROLO[3,2-C]PYRIDIN-4-ONE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | ERBB2, EGFR, ERBB3 | CHRM2 1569/4885CHRM1 2149/4885CHRM3 2472/4885 |
| US-20210238162-A1 | CHEMICAL COMPOUNDS | HPGDS, PTGS1, PTGIS | CHRM2 1785/4885CHRM1 1661/4885CHRM3 2410/4885 |
| US-20170096411-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS PIM KINASE INHIBITORS | PIM1, PIM2, PIM3 | CHRM2 4853/4885CHRM1 4773/4885CHRM3 4768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.